MCID: EPN002
MIFTS: 53

Ependymoma

Categories: Rare diseases, Cancer diseases, Neuronal diseases, Genetic diseases

Aliases & Classifications for Ependymoma

MalaCards integrated aliases for Ependymoma:

Name: Ependymoma 49 55 28 51 69
Tanycytic Ependymoma 49 69
Papillary Ependymoma 49 69
Cellular Ependymoma 49 69
Who Grade Ii Ependymal Neoplasm 49
Epithelial Ependymoma 49
Clear Cell Ependymoma 49
Ependymoma, Familial 49

Characteristics:

Orphanet epidemiological data:

55
ependymoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe); Age of onset: All ages;

Classifications:

Orphanet: 55  
Rare neurological diseases


External Ids:

Orphanet 55 ORPHA251636
UMLS via Orphanet 70 C0014474
ICD10 via Orphanet 33 D43.2

Summaries for Ependymoma

NIH Rare Diseases : 49 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 251636Disease definitionEpendymoma is the most frequent intramedullary tumor in adults (but accounts for only 10-12% of pediatric central nervous system tumors), and can be benign or anaplastic. Ependymoma arise from the ependymal cells of the cerebral ventricles, corticle rests and central canal of the spinal cord, and manifest with variable symptoms such headache, vomiting, seizures, focal neurological signs and loss of vision and can cause obstructive hydrocephalus in some cases.Visit the Orphanet disease page for more resources. Last updated: 3/20/2014

MalaCards based summary : Ependymoma, also known as tanycytic ependymoma, is related to malignant ependymoma and benign ependymoma. An important gene associated with Ependymoma is C11orf95 (Chromosome 11 Open Reading Frame 95), and among its related pathways/superpathways are DNA Damage and Neuroscience. The drugs Vincristine and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and bone, and related phenotypes are respiratory system and vision/eye

Related Diseases for Ependymoma

Diseases in the Ependymoma family:

Benign Ependymoma Malignant Ependymoma
Malignant Adult Ependymoma

Diseases related to Ependymoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 294)
# Related Disease Score Top Affiliating Genes
1 malignant ependymoma 33.7 GFAP NF2 RELA
2 benign ependymoma 33.6 GFAP NF2 SYP
3 myxopapillary ependymoma 33.6 GFAP MUC1 S100B VIM
4 cellular ependymoma 33.5 GFAP RELA SYP
5 brain ependymoma 33.4 EGFR MKI67
6 anaplastic ependymoma 32.7 GFAP MUC1 NF2 RELA S100B SYP
7 tanycytic ependymoma 32.7 GFAP NES NF2 SYP
8 clear cell ependymoma 32.6 GFAP MUC1 NF2 RELA SYP VIM
9 papillary ependymoma 32.6 GFAP NES S100B SYP
10 subependymal glioma 31.9 GFAP SYP
11 subependymoma 31.7 GFAP NES SYP
12 pilomyxoid astrocytoma 30.3 GFAP SYP
13 papilloma of choroid plexus 30.1 GFAP MUC1 S100B SYP
14 hemangioblastoma 30.1 GFAP MUC1 S100B SYP
15 medulloblastoma 30.0 GFAP MGMT NES SYP TIMP3 TP73
16 neuroma 29.8 GFAP NF2 S100B
17 angiocentric glioma 29.8 GFAP S100B SYP VIM
18 neurofibroma 29.5 MUC1 NF2 S100B SYP
19 hydrocephalus 29.5 GFAP NES SYP
20 ependymoblastoma 29.4 GFAP NES VIM
21 pilocytic astrocytoma 29.4 GFAP MGMT SYP TIMP3
22 chordoma 29.3 EGFR GFAP MUC1 S100B VIM
23 oligodendroglioma 29.3 EGFR GFAP MGMT SYP TP73
24 central neurocytoma 29.2 GFAP NES SYP
25 malignant glioma 29.2 EGFR GFAP MGMT
26 chordoid meningioma 29.1 GFAP MUC1 S100B SYP VIM
27 ganglioglioma 28.9 GFAP NES S100B SYP
28 astroblastoma 28.9 GFAP NES SYP VIM
29 medulloepithelioma 28.9 GFAP NES SYP VIM
30 meningioma, familial 28.5 GFAP MKI67 MUC1 NF2 S100B SYP
31 astrocytoma 28.5 EGFR GFAP MGMT NES S100B SYP
32 gliosarcoma 28.1 EGFR GFAP MGMT NES S100B VIM
33 pediatric ependymoma 12.3
34 spinal cord ependymoma 12.1
35 pediatric supratentorial ependymoma 12.0
36 pediatric infratentorial ependymoma 12.0
37 low grade ependymoma 11.9
38 mixed astrocytoma-ependymoma 11.9
39 brain stem ependymoma 11.8
40 malignant adult ependymoma 11.8
41 adult brain ependymoma 11.8
42 adult spinal cord ependymoma 11.8
43 mixed astrocytoma-ependymoma-oligodendroglioma 11.8
44 parietal lobe ependymoma 11.8
45 glioma 11.2
46 multiple endocrine neoplasia, type i 11.2
47 glioma susceptibility 1 11.1
48 neurofibromatosis, type ii 10.9
49 glioma susceptibility 2 10.9
50 glioma susceptibility 3 10.9

Graphical network of the top 20 diseases related to Ependymoma:



Diseases related to Ependymoma

Symptoms & Phenotypes for Ependymoma

MGI Mouse Phenotypes related to Ependymoma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 respiratory system MP:0005388 9.5 TIMP3 TP73 VIM EGFR MGMT NF2
2 vision/eye MP:0005391 9.17 EGFR GFAP NF2 RELA TIMP3 TP73

Drugs & Therapeutics for Ependymoma

Drugs for Ependymoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 300)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
2
Etoposide Approved Phase 2, Phase 3, Phase 1, Early Phase 1 33419-42-0 36462
3
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
4
Methotrexate Approved Phase 3,Phase 2,Phase 1,Early Phase 1 1959-05-2, 59-05-2 126941
5
Carboplatin Approved Phase 2, Phase 3, Phase 1 41575-94-4 10339178 38904 498142
6
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
7
Dacarbazine Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 4342-03-4 5351166
8
Temozolomide Approved, Investigational Phase 2, Phase 3, Phase 1, Early Phase 1 85622-93-1 5394
9 Thiotepa Approved, Investigational Phase 2, Phase 3, Phase 1 52-24-4 5453
10
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
11
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
12
Valproic Acid Approved, Investigational Phase 2, Phase 3,Phase 1 99-66-1 3121
13
Donepezil Approved Phase 3,Phase 2,Early Phase 1 120014-06-4 3152
14
Histamine Approved, Investigational Phase 3,Phase 2 51-45-6, 75614-87-8 774
15
Cyproheptadine Approved Phase 3,Phase 2 129-03-3 2913
16
Ondansetron Approved Phase 3 99614-02-5 4595
17
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
18
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
19
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
20
Methylphenidate Approved, Investigational Phase 3 20748-11-2, 113-45-1 4158
21
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1,Early Phase 1 58-05-9 143 6006
22
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Early Phase 1 59-30-3 6037
23 Trofosfamide Investigational Phase 2, Phase 3 22089-22-1
24 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
25 Alkylating Agents Phase 2, Phase 3, Phase 1, Early Phase 1
26 Central Nervous System Depressants Phase 3,Phase 2,Phase 1
27 Folic Acid Antagonists Phase 3,Phase 2,Phase 1,Early Phase 1
28 Topoisomerase Inhibitors Phase 2, Phase 3, Phase 1, Early Phase 1
29 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1,Early Phase 1
30 Dermatologic Agents Phase 3,Phase 2,Phase 1,Early Phase 1
31 Vitamin B Complex Phase 3,Phase 2,Phase 1,Early Phase 1
32 Etoposide phosphate Phase 2, Phase 3, Phase 1, Early Phase 1
33 Immunosuppressive Agents Phase 2, Phase 3, Phase 1, Early Phase 1
34 Antimetabolites Phase 3,Phase 2,Phase 1,Early Phase 1
35 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Early Phase 1
36 Antimitotic Agents Phase 3,Phase 2,Phase 1
37 Liver Extracts Phase 3,Phase 2,Phase 1
38 Antineoplastic Agents, Phytogenic Phase 2, Phase 3, Phase 1, Early Phase 1
39 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Early Phase 1
40
Histamine Phosphate Phase 3,Phase 2 51-74-1 65513
41 Dexamethasone acetate Phase 3,Phase 2,Phase 1 1177-87-3
42
Serotonin Phase 3,Phase 2 50-67-9 5202
43 Analgesics Phase 3,Phase 2,Phase 1
44 Adjuvants, Anesthesia Phase 3
45 Central Nervous System Stimulants Phase 3,Phase 2
46 Serotonin Agents Phase 3,Phase 2
47 Serotonin Antagonists Phase 3,Phase 2
48 Cholinergic Agents Phase 3,Phase 2,Early Phase 1
49 GABA Agents Phase 2, Phase 3,Phase 1
50 Narcotics Phase 3

Interventional clinical trials:

(show top 50) (show all 247)

# Name Status NCT ID Phase Drugs
1 Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children Unknown status NCT00749723 Phase 2, Phase 3 carboplatin;etoposide;temozolomide;thiotepa, carboplatin, etoposide;temozolomide, thiotepa;etoposide;trofosfamide/etoposide
2 SCRT Versus Conventional RT in Children and Young Adults With Low Grade and Benign Brain Tumors Unknown status NCT00517959 Phase 3
3 Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
4 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
5 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
6 Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
7 An International Clinical Program for the Diagnosis and Treatment of Children With Ependymoma Recruiting NCT02265770 Phase 2, Phase 3 16 weeks of VEC + CDDP;VEC + HD-MTX;Chemotherapy + Valproate;VEC;Chemotherapy
8 Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma Recruiting NCT01096368 Phase 3 liposomal vincristine sulfate;carboplatin;cyclophosphamide;etoposide;cisplatin
9 Observing Young Patients With Ependymoma Undergoing Standard Combination Chemotherapy Active, not recruiting NCT00683319 Phase 3 carboplatin;cisplatin;cyclophosphamide;methotrexate;vincristine sulfate
10 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
11 Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
12 High-Dose Methotrexate in Treating Young Patients With Residual Ependymoma Unknown status NCT00287924 Phase 2 methotrexate
13 Etoposide in Treating Young Patients With Relapsed Ependymoma Unknown status NCT00278252 Phase 2 etoposide
14 Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma Unknown status NCT00826241 Phase 2 Temozolomide;Lapatinib
15 Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
16 The Use of 5-aminolevulinic Acid (ALA) as an Intraoperative Tumor Marker for Resection of Pediatric Central Nervous System (CNS) Tumors Unknown status NCT02050243 Phase 1, Phase 2 5ALA
17 Proton Beam Radiation Therapy in Treating Patients With Low Grade Gliomas Unknown status NCT01024907 Phase 1, Phase 2
18 A Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain Unknown status NCT01403311 Phase 2 5-Aminolevuline Acid
19 Combination Chemotherapy With or Without Radiation Therapy in Treating Children With Brain Tumors Unknown status NCT00281905 Phase 2 carboplatin;cisplatin;cyclophosphamide;methotrexate;vincristine sulfate
20 Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm Unknown status NCT00009854 Phase 1, Phase 2 carmustine in ethanol
21 Combination Chemotherapy Followed by Radiation Therapy in Treating Children With Localized Ependymoma Completed NCT00004224 Phase 2 cyclophosphamide;etoposide;vincristine sulfate
22 Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma Completed NCT00883688 Phase 2 Bevacizumab;Lapatinib
23 Etoposide Plus Cisplatin in Treating Patients With Recurrent Ependymomas Completed NCT00002876 Phase 2 cisplatin;etoposide
24 Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma Completed NCT01462695 Phase 2 Sunitinib Malate
25 Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma Completed NCT00381797 Phase 2 Irinotecan Hydrochloride
26 Combination Chemotherapy Followed by Radiation Therapy in Treating Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma Completed NCT00006258 Phase 2 cisplatin;cyclophosphamide;etoposide;methotrexate;vincristine sulfate
27 Combination Chemotherapy Plus Radiation Therapy in Treating Adult Patients With Brain Cancer Completed NCT00003309 Phase 2 cisplatin;cyclophosphamide;etoposide;vincristine sulfate
28 Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors Completed NCT01836549 Phase 2 imetelstat sodium
29 Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors Completed NCT00095940 Phase 1, Phase 2 lapatinib ditosylate
30 Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma Completed NCT00008008 Phase 2 cyclophosphamide;thiotepa
31 A Study of Pemetrexed in Children With Recurrent Cancer Completed NCT00520936 Phase 2 pemetrexed
32 A Study for Image-Guided Radiation Therapy in Pediatric Brain Tumors and Side Effects Completed NCT00187226 Phase 2
33 Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma Completed NCT00006102 Phase 2 becatecarin
34 Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2) Completed NCT01207687 Phase 2
35 Phenylbutyrate to Treat Children With Progressive or Recurrent Brain Tumors Completed NCT00006450 Phase 2 Phenylbutyrate
36 A Phase I/II Study of the Photon Radiosurgery System Completed NCT00179907 Phase 1, Phase 2
37 Irinotecan in Treating Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
38 Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2 Completed NCT01419639 Phase 2 Everolimus (RAD001) , Afinitor®
39 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2 bevacizumab;placebo
40 Oxaliplatin in Treating Children With Recurrent or Refractory Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor Completed NCT00047177 Phase 2 Oxaliplatin
41 Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Completed NCT00091182 Phase 2 oxaliplatin
42 Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy Completed NCT00463203 Phase 2 Bevacizumab;Irinotecan
43 Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma Completed NCT00058123 Phase 2 poly ICLC
44 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers Completed NCT00002752 Phase 1, Phase 2
45 Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer Completed NCT00014573 Phase 2 carmustine;cisplatin;cyclophosphamide;paclitaxel
46 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
47 Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors Completed NCT01032200 Phase 2 Armodafinil
48 Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors Completed NCT00541138 Phase 2 carboplatin;tamoxifen citrate;topotecan hydrochloride
49 Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma Completed NCT00498927 Phase 2 temozolomide
50 Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas Completed NCT00274755 Phase 2 chemotherapy

Search NIH Clinical Center for Ependymoma

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Genetic Tests for Ependymoma

Genetic tests related to Ependymoma:

# Genetic test Affiliating Genes
1 Ependymoma 28

Anatomical Context for Ependymoma

MalaCards organs/tissues related to Ependymoma:

38
Brain, Spinal Cord, Bone, Bone Marrow, Liver, Testes, T Cells

Publications for Ependymoma

Articles related to Ependymoma:

(show top 50) (show all 996)
# Title Authors Year
1
Ependymoma Superenhancer Profiling Reveals Potential Therapeutic Targets. ( 29330264 )
2018
2
RELA fusion-positive anaplastic ependymoma: molecular characterization and advanced MR imaging. ( 29063976 )
2018
3
Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling. ( 29258295 )
2018
4
Outcomes After Reirradiation for Recurrent Pediatric Intracranial Ependymoma. ( 29229328 )
2018
5
Metastases of spinal myxopapillary ependymoma: unique characteristics and clinical management. ( 29219779 )
2018
6
Teaching Case 2-2018: Sclerosing myxopapillary ependymoma mimicking whorling-sclerosing meningioma. ( 29436365 )
2018
7
Intramedullary ependymoma: long-term outcome after surgery. ( 29280009 )
2018
8
Extraspinal sacrococcygeal ependymoma masquerading as sacrococcygeal teratoma in the pediatric patient. ( 29138922 )
2018
9
An Extremely Rare Case of Back and Hip Pain due to the Metastasis of Late Recurrent Myxopapillary Ependymoma to the Inguinal Lymph Node. ( 29166763 )
2018
10
Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: Implications for PD-1-targeted therapy. ( 29350470 )
2018
11
Resistance promoting effects of ependymoma treatment revealed through genomic analysis of multiple recurrences in a single patient. ( 29440180 )
2018
12
Unique combination of myxopapillary ependymoma and conus lipoma with subcutaneous extension in an 11-month-old child. ( 29380114 )
2018
13
Keyhole Contralateral Interhemispheric Endoscopic-Assisted Resection of an Ependymoma of the Third Ventricle. ( 29351681 )
2018
14
Immunohistochemical features of giant cell ependymoma of the filum terminale with unusual clinical and radiological presentation. ( 28088216 )
2017
15
Rare association of secondary superficial siderosis caused by a fourth ventricle hemorrhagic ependymoma mimicking a cavernoma: Case report and literature review. ( 28217393 )
2017
16
Rethinking childhood ependymoma: a retrospective, multi-center analysis reveals poor long-term overall survival. ( 28733870 )
2017
17
Myxopapillary Ependymoma of Lumbar Soft Tissue: A Case Report With Gene Expression Evaluation. ( 29254456 )
2017
18
Two Cases of Spinal Tanycytic Ependymoma Associated with Neurofibromatosis Type 2. ( 28345553 )
2017
19
Prognostic relevance of miR-124-3p and its target TP53INP1 in pediatric ependymoma. ( 28437838 )
2017
20
Put away your microscopes: the ependymoma molecular era has begun. ( 28885433 )
2017
21
Radical, Staged Approach to Extensive Posterior Fossa Pediatric Ependymoma: 3-Dimensional Operative Video. ( 29029279 )
2017
22
Current therapy and the evolving molecular landscape of paediatric ependymoma. ( 27866097 )
2017
23
Medulloblastoma and ependymoma cells display increased levels of 5-carboxylcytosine and elevated TET1 expression. ( 28228863 )
2017
24
Unusual cauda equina syndrome due to multifocal ependymoma infiltrated by lymphoma. ( 29354750 )
2017
25
Regional Spinal Cord Atrophy Is Associated with Poor Outcome After Surgery on Intramedullary Spinal Cord Ependymoma: A New Aspect of Delayed Neurological Deterioration. ( 28104525 )
2017
26
Mixed hemangioblastoma and ependymoma collision tumor of the cerebellum. ( 28766496 )
2017
27
A brain ependymoma with psychiatric manifestation. ( 29332363 )
2017
28
"Drop" Metastases from an Operated Case of Intracranial Anaplastic Ependymoma Identified on Fluoro-2-deoxyglucose Positron Emission Tomography/Computed Tomography. ( 28242994 )
2017
29
TERT Promoter Mutations but not the Alternative Lengthening of Telomeres Phenotype Are Present in a Subset of Ependymomas and Are Associated With Adult Onset and Progression to Ependymosarcoma. ( 28040793 )
2017
30
Four-hand suction-irrigation technique leads to gross total resection and long-term-progression free survival in fourth ventricular ependymoma. ( 28804042 )
2017
31
Extra-axial ependymoma of the cerebral convexity: A very rare intracranial adult tumor. ( 28059629 )
2017
32
Cerebellar ependymoma with overlapping features of clear-cell and tanycytic variants mimicking hemangioblastoma: a case report and literature review. ( 28320419 )
2017
33
Outcomes following proton therapy for pediatric ependymoma. ( 29239262 )
2017
34
Spinal intramedullary ependymoma: surgical approaches and outcome. ( 28748910 )
2017
35
Spinal cord anaplastic ependymoma induced by radiation treatment of breast cancer. ( 28555490 )
2017
36
Patterns of failure after radiotherapy for pediatric patients with intracranial ependymoma. ( 28089483 )
2017
37
Prognostic Factors and Survival Outcomes of Intracranial Ependymoma Treated with Multimodality Approach. ( 29333005 )
2017
38
Spinal myxopapillary ependymoma presenting with low back pain and subarachnoid hemorrhage. ( 28737370 )
2017
39
Remarkable efficacy of temozolomide for relapsed spinal myxopapillary ependymoma with multiple recurrence and cerebrospinal dissemination: a case report and literature review. ( 29270703 )
2017
40
LncRNA LINC00880 promotes cell proliferation, migration and invasion while inhibiting apoptosis by targeting CACNG5 through the MAPK signaling pathway in spinal cord ependymoma. ( 29215699 )
2017
41
Characterization of 2 Novel Ependymoma Cell Lines With Chromosome 1q Gain Derived From Posterior Fossa Tumors of Childhood. ( 28863455 )
2017
42
Recursive partitioning analysis for disease progression in adult intracranial ependymoma patients. ( 28890044 )
2017
43
Encouraging option of multi-staged gross total resection for a C11orf-RelA fusion-positive supratentorial anaplastic ependymoma. ( 28831588 )
2017
44
Rapid autopsy of a patient with recurrent anaplastic ependymoma. ( 28942746 )
2017
45
A case of clear cell ependymoma with bizarre aggressiveness: Are we underestimating its ferocity? ( 28879912 )
2017
46
Intracranial neurenteric cyst mimicking an ependymoma: imaging features, pathologic correlation and review of literature. ( 28505503 )
2017
47
Anaplastic myxopapillary ependymoma in an infant: Case report and literature review. ( 28580214 )
2017
48
The Pediatric Ependymoma Protein Database (PEPD). ( 29124086 )
2017
49
Giant Cell Ependymoma of the Lateral Ventricle: Case Report, Literature Review, and Analysis of Prognostic Factors and Genetic Profile. ( 28943417 )
2017
50
Erratum: Rare association of secondary superficial siderosis caused by a fourth ventricle hemorrhagic ependymoma mimicking a cavernoma: Case report and literature review. ( 28540135 )
2017

Variations for Ependymoma

Cosmic variations for Ependymoma:

9 (show all 18)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM5977674 RANBP2 central nervous system,spinal cord,glioma,anaplastic c.5736T>G p.S1912R 3
2 COSM150426 KMT2C central nervous system,spinal cord,glioma,anaplastic c.2963G>T p.C988F 3
3 COSM1179671 KMT2C central nervous system,spinal cord,glioma,anaplastic c.925C>T p.P309S 3
4 COSM253767 KMT2C central nervous system,spinal cord,glioma,anaplastic c.2959T>C p.Y987H 3
5 COSM227271 HSP90AB1 central nervous system,spinal cord,glioma,anaplastic c.2156G>A p.R719H 3
6 COSM327928 H3F3A central nervous system,spinal cord,glioma,anaplastic c.83A>T p.K28M 3
7 COSM3164376 GATA4 central nervous system,spinal cord,glioma,anaplastic c.1273G>A p.D425N 3
8 COSM5977673 ALOX12B central nervous system,spinal cord,glioma,anaplastic c.53C>T p.T18I 3
9 COSM5977672 central nervous system,spinal cord,glioma,anaplastic c.53C>T p.T18I 3
10 COSM253768 central nervous system,spinal cord,glioma,anaplastic c.2959T>C p.Y987H 3
11 COSM1179670 central nervous system,spinal cord,glioma,anaplastic c.925C>T p.P309S 3
12 COSM150427 central nervous system,spinal cord,glioma,anaplastic c.2963G>T p.C988F 3
13 COSM4593267 central nervous system,spinal cord,glioma,anaplastic c.32C>T p.A11V 3
14 COSM23869 NF2 central nervous system,spinal cord,glioma,ependymoma Grade II c.675+1G>A p.? 2
15 COSM23667 NF2 central nervous system,spinal cord,glioma,ependymoma Grade II c.1396C>T p.R466* 2
16 COSM24624 NF2 central nervous system,spinal cord,glioma,ependymoma Grade II c.675+5G>A p.? 2
17 COSM22432 NF2 central nervous system,spinal cord,glioma,ependymoma Grade II c.592C>T p.R198* 2
18 COSM23159 MEN1 central nervous system,spinal cord,glioma,ependymoma Grade II c.1413G>A p.W471* 2

Copy number variations for Ependymoma from CNVD:

7 (show top 50) (show all 1024)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13823 1 1 7200000 Deletion Ependymoma
2 15495 1 116080654 116108285 Amplification NHLH2 Ependymoma
3 15648 1 117745152 117779348 Deletion MAN1A2 Ependymoma
4 19381 1 150034000 245120000 Amplification Ependymoma
5 19382 1 150034000 245120000 Amplification Ependymoma
6 26308 1 198898833 198920273 Amplification LGR6 Ependymoma
7 31595 1 2869431 2902617 Amplification TLR5 Ependymoma
8 31803 1 3118000 5001000 Deletion Ependymoma
9 38299 10 101279725 101300855 Deletion NKX2 Ependymoma
10 38453 10 102724768 102752246 Deletion LZTS2 Ependymoma
11 38454 10 102724768 102752246 Deletion MRPL43 Ependymoma
12 38455 10 102724768 102752246 Deletion PEO1 Ependymoma
13 38456 10 102724768 102752246 Deletion SEMA4G Ependymoma
14 38866 10 105634726 105742493 Deletion OBFC1 Ependymoma
15 38867 10 105634726 105742493 Deletion SLK Ependymoma
16 38979 10 106855945 106907237 Deletion SORCS3 Ependymoma
17 39169 10 11151805 11236375 Deletion CUGBP2 Ependymoma
18 40763 10 13344307 13497936 Deletion PHYH Ependymoma
19 40764 10 13344307 13497936 Deletion SEPHS1 Ependymoma
20 40806 10 133827559 133847021 Amplification C10orf39 Ependymoma
21 40809 10 133852261 133910912 Deletion DPYSL4 Ependymoma
22 40810 10 133852261 133910912 Deletion STK32C Ependymoma
23 40887 10 134410586 134892955 Deletion C10orf92 Ependymoma
24 40888 10 134410586 134892955 Deletion C10orf93 Ependymoma
25 40889 10 134410586 134892955 Deletion GPR123 Ependymoma
26 40890 10 134410586 134892955 Deletion INPP5A Ependymoma
27 40891 10 134410586 134892955 Deletion KNDC1 Ependymoma
28 40892 10 134410586 134892955 Deletion NKX6 Ependymoma
29 41033 10 135073302 135095235 Amplification ECHS1 Ependymoma
30 41034 10 135073302 135095235 Amplification PAOX Ependymoma
31 41074 10 135176625 135276748 Deletion CYP2E1 Ependymoma
32 41075 10 135176625 135276748 Deletion FLJ44653 Ependymoma
33 41076 10 135176625 135276748 Deletion SYCE1 Ependymoma
34 41910 10 25665327 25756077 Deletion GPR158 Ependymoma
35 42307 10 3169189 3180797 Deletion PITRM1 Ependymoma
36 44077 10 5175582 5187881 Deletion AKR1CL1 Ependymoma
37 44224 10 53651276 53712562 Deletion PRKG1 Ependymoma
38 44704 10 6170011 6268419 Deletion RBM17 Ependymoma
39 45199 10 68970214 69114993 Deletion CTNNA3 Ependymoma
40 45273 10 69645873 69701073 Deletion ATOH7 Ependymoma
41 45408 10 70846341 70896472 Deletion TSPAN15 Ependymoma
42 45468 10 71234506 71351772 Deletion COL13A1 Ependymoma
43 45538 10 71990162 72295747 Deletion ADAMTS14 Ependymoma
44 45539 10 71990162 72295747 Deletion C10orf27 Ependymoma
45 45540 10 71990162 72295747 Deletion KIAA1274 Ependymoma
46 45541 10 71990162 72295747 Deletion PRF1 Ependymoma
47 45542 10 71990162 72295747 Deletion SGPL1 Ependymoma
48 45578 10 72636128 72774965 Deletion SLC29A3 Ependymoma
49 45579 10 72636128 72774965 Deletion UNC5B Ependymoma
50 45628 10 73121579 73231404 Deletion C10orf54 Ependymoma

Expression for Ependymoma

Search GEO for disease gene expression data for Ependymoma.

Pathways for Ependymoma

GO Terms for Ependymoma

Biological processes related to Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to organic cyclic compound GO:0014070 9.58 EGFR MGMT RELA
2 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.46 EGFR RELA
3 regulation of neuronal synaptic plasticity GO:0048168 9.43 S100B SYP
4 astrocyte development GO:0014002 9.37 GFAP VIM
5 intermediate filament organization GO:0045109 9.32 GFAP VIM
6 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.26 MUC1 TP73
7 Bergmann glial cell differentiation GO:0060020 9.16 GFAP VIM
8 response to cobalamin GO:0033590 8.96 EGFR RELA
9 intermediate filament-based process GO:0045103 8.62 GFAP VIM

Molecular functions related to Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.17 EGFR GFAP RELA S100B SYP TP73

Sources for Ependymoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....